Trial Profile
A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride (HCl) Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD) in Fed Condition
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2021
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Rhodes Pharmaceuticals
- 10 Aug 2020 Status changed to completed.
- 10 Aug 2020 Results published in the Pediatric Drugs.
- 04 Feb 2016 According to ClinicalTrials.gov record, the treatment table has been amended.